Online inquiry

IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12156MR)

This product GTTS-WQ12156MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12156MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14035MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ10421MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ6834MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ5187MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ11743MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ11984MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ12596MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ11482MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW